HERmark® versus FISH

HERmark® was shown to outperform fluorescent in situ hybridization (FISH) at determining patient outcomes in patients with metastatic breast cancer treated with trastuzumab. HERmark results correlate highly with trastuzumab outcomes in the Hershey/Vienna Council cohort (n=103).1

Within the group of patients who were FISH-positive, those with a low HER-2 total had a shorter time to progression (TTP) than those who had a high HER-2 total.